Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Overview
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Companies Involved in Therapeutics Development
Amogen Pharma Pvt Ltd
Beijing GeneCradle Technology Co Ltd
Biocad
CANbridge Life Sciences Ltd
F. Hoffmann-La Roche Ltd
Huida (Shanghai) Biotechnology Co Ltd
Novartis AG
Novartis Gene Therapies
Sarepta Therapeutics Inc
Shift Pharmaceuticals
Spotlight Innovation Inc (Ictive)
Suzhou Gessist Therapeutics Co Ltd
Voyager Therapeutics Inc
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Drug Profiles
ALB-111 - Drug Profile
Product Description
Mechanism Of Action
ANB-4 - Drug Profile
Product Description
Mechanism Of Action
Antisense Oligonucleotide to Activate SMN2 for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
History of Events
braplam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
E-1V111 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GC-101 - Drug Profile
Product Description
Mechanism Of Action
GEN-8010 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate SMN1 for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
HG-001 - Drug Profile
Product Description
Mechanism Of Action
osemnogene abeparvovec - Drug Profile
Product Description
Mechanism Of Action
History of Events
osemnogene abeparvovec - Drug Profile
Product Description
Mechanism Of Action
PMO-25 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Resagen - Drug Profile
Product Description
Mechanism Of Action
History of Events
risdiplam - Drug Profile
Product Description
Mechanism Of Action
History of Events
Second-Generation scAAV9 Gene Therapy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules 2 to Activate SMN2 for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate SMN2 for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
STL-182 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Dormant Products
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Discontinued Products
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Amogen Pharma Pvt Ltd, 2022
Pipeline by Beijing GeneCradle Technology Co Ltd, 2022
Pipeline by Biocad, 2022
Pipeline by CANbridge Life Sciences Ltd, 2022
Pipeline by F. Hoffmann-La Roche Ltd, 2022
Pipeline by Huida (Shanghai) Biotechnology Co Ltd, 2022
Pipeline by Novartis AG, 2022
Pipeline by Novartis Gene Therapies, 2022
Pipeline by Sarepta Therapeutics Inc, 2022
Pipeline by Shift Pharmaceuticals, 2022
Pipeline by Spotlight Innovation Inc (Inactive), 2022
Pipeline by Suzhou GenAssist Therapeutics Co Ltd, 2022
Pipeline by Voyager Therapeutics Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022